ClinicalTrials.gg
RecruitingNCT07405086Updated Oct 13, 2026

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

A Phase 4 interventional study of Biospecimen Collection and Immune Checkpoint Inhibitor in Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma and Advanced Hepatocellular Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionnone(registry's first term: Squamous Cell Carcinoma of Head and Neck)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Squamous Cell Carcinoma of Head and Neck, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 13, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 10:30 am) or afternoon (12:30pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare progression-free survival among participants receiving immunotherapy based on time of day (ToD) administration (early versus [vs.] late).

SECONDARY OBJECTIVES:

I. To compare overall survival among participants receiving immunotherapy based on ToD administration (am vs. pm).

II. To compare rates of significant immune-related adverse events (irAEs) based on ToD administration (am vs. pm).

EXPLORATORY OBJECTIVES:

I. To compare objective responses among participants receiving immunotherapy based on ToD administration (am vs. pm).

II. To compare disease control among participants receiving immunotherapy based on ToD administration (am vs. pm).

III. To compare the duration of response among participants receiving immunotherapy based on ToD administration (am vs. pm).

OUTLINE: Patients are randomized to 1 of 2 cohorts.

AM COHORT: Patients receive standard of care immunotherapy before 10:30 for 4 doses in the absence of disease progression or unacceptable toxicity. Subsequent doses may be given per standard of care timing. Patients also undergo blood sample collection throughout the study.

PM COHORT: Patients receive standard of care immunotherapy after 13:30 for 4 doses in the absence of disease progression or unacceptable toxicity. Subsequent doses may be given per standard of care timing. Patients also undergo blood sample collection throughout the study.

After completion of immunotherapy treatment, patients are followed up every 6 months for 2 years.

02

Conditions studied

  • Advanced Biliary Tract Carcinoma
  • Advanced Head and Neck Squamous Cell Carcinoma
  • Advanced Hepatocellular Carcinoma
  • Advanced Lung Non-Small Cell Carcinoma
  • Advanced Malignant Solid Neoplasm
  • Advanced Melanoma
  • Advanced Renal Cell Carcinoma
  • Metastatic Biliary Tract Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hepatocellular Carcinoma
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Melanoma
  • Metastatic Renal Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
03

In context

Lead sponsor

OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must provide written before any study-specific procedures or interventions are performed
  • Aged ≥ 18 years
  • confirmed advanced/ solid tumor as follows:

    • Non small cell lung cancer (NSCLC) (non-actionable genomic alteration, inhibitor [ICI]-eligible)
    • Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (platinum-eligible),
    • Renal cell carcinoma (RCC)
    • Biliary-tract cancer (BTC)
    • Hepatocellular carcinoma (HCC)
    • Melanoma
    • Gastroesophageal cancer, including esophageal cancer, gastroesophageal cancer, or gastric cancer
  • Planned to receive a Food and Drug Administration (FDA)-approved immune check point inhibitor (e.g., , anti-PD-L1, anti-CTLA4) regimen for the treatment of their
  • per (RECIST) 1.1

Exclusion criteria

Exclusion Criteria:

  • Prior ICI-based regimen for treatment of cancer
  • Current or prior use of medication within 28 days before planned standard-of-care immunotherapy infusion, with the exception of intranasal and inhaled or systemic corticosteroids at physiological doses not exceeding 10 mg/day of prednisone (or equivalent corticosteroid)
  • Uncontrolled disease requiring immunosuppression
  • Known Active, uncontrolled central nervous system (CNS)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Treatment (AM cohort)

    Patients receive standard of care immunotherapy before 10:30 for 4 doses in the absence of disease progression or unacceptable toxicity. Subsequent doses may be given per standard of care timing. Patients also undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Drug: Immune Checkpoint Inhibitor

  • Experimental
    Treatment (PM cohort)

    Patients receive standard of care immunotherapy after 13:30 for 4 doses in the absence of disease progression or unacceptable toxicity. Subsequent doses may be given per standard of care timing. Patients also undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Drug: Immune Checkpoint Inhibitor

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive immune checkpoint inhibitor therapy

    Also known as: ICI

06

What researchers measure

Primary outcomes

  1. Progression free survival

    The associated 95% confidence interval (CI) for each treatment group will be estimated using the Kaplan-Meier method. The stratified hazard ratio (HR) and its 95% CI will be estimated using a Cox proportional-hazard model with treatment group as the independent variable and stratified by the same randomization stratification factors as were used for the log-rank test.

    Time frame: From date of randomization to date of first progression or death (any cause), whichever occurs first (up to 2 years from date of last dose of standard-of-care immune checkpoint inhibitor [ICI])

Secondary outcomes

  1. Overall survival (OS)

    The median duration of OS and the associated 95% CI for each treatment group will be estimated using the Kaplan-Meier method. The stratified HR and its 95% CI will be estimated using a Cox proportional-hazard model with treatment group as the independent variable and stratified by the same randomization stratification factors as were used for the log-rank test.

    Time frame: From date of randomization to date of death (any cause) up to 2 years from date of last dose of standard-of-care ICI

  2. Incidence of immune related adverse event (irAE) related time to treatment discontinuation

    Will be analyzed for all evaluable patients using a Kaplan-Meyer survival analysis. The number of events, percentiles for the time to discontinuation for irAE-related reasons (25%, 50% (median), and 75% percentiles), and the proportion of participants who discontinued standard-of-care for irAE-related reasons will be summarized by treatment group.

    Time frame: From date of first dose of standard-of-care ICI to date of last dose of standard-of-care ICI (an average of 2 years).

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Apr 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 12, 2026
StartActual
Apr 24, 2026was Jun 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 8, 2026→Apr 24, 2026
Oct 13, 2026
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedNon small cell lung cancer (NSCLC) (drivernon-negativeactionable genomic alteration, immune checkpoint inhibitor [ICI]-eligible)
  • AddedGastroesophageal cancer, including esophageal cancer, gastroesophageal cancer, or gastric cancer
Exclusion criteria
  • EditedKnown Active, uncontrolled central nervous system (CNS) metastases
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • OHSU Knight Cancer Institute · Portland, United StatesContact t•••@ohsu.edu→t•••@ohsu.edu
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Jun 8, 2026→Apr 24, 2026
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedNon small cell lung cancer (NSCLC) (drivernon-negativeactionable genomic alteration, immune checkpoint inhibitor [ICI]-eligible)
    • AddedGastroesophageal cancer, including esophageal cancer, gastroesophageal cancer, or gastric cancer
    Exclusion criteria
    • EditedKnown Active, uncontrolled central nervous system (CNS) metastases
    Site contacts Changed at 1 site. See the sites
    Show the site
    • OHSU Knight Cancer Institute · Portland, United StatesContact t•••@ohsu.edu→t•••@ohsu.edu
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07405086
Responsible party
Rajat Thawani (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Feb 12, 2026
Start date
Apr 24, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Rajat Thawani
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion